Supply of CAR-T medicines for the Canary Islands Health Service

Summary

The Canary Islands Health Service is establishing a dynamic purchasing system for CAR-T medicines for cell therapy and other evolving advanced cell-based therapies. The medicines are intended to treat adults with relapsed or refractory diffuse large B-cell lymphoma, relapsed or refractory mantle cell lymphoma, and relapsed or refractory multiple myeloma. The system covers one cell-therapy category; the needs and any division into lots will be specified in subsequent procurements. Estimated purchases total EUR 40,037,508 over five years.